Figure 6.
Activation of the BMP signaling pathway protects glioma cells from cytotoxic injury. (A) Cell viability following treatment of G144 cells with temozolomide and radiation, with BMP4 and LY364947 or TGF-β1 and noggin, compared to control (n = 3, *p < 0.05). (B) Cell viability following treatment of G179 cells with temozolomide and radiation, with BMP4 and LY364947 or TGF-β1 and noggin, compared to control (n = 3, *p < 0.05). (C) Cell viability following treatment of BT046 cells with temozolomide and radiation, with BMP4 and LY364947 or TGF-β1 and noggin, compared to control (n = 3, *p < 0.05). (D) Western blot analysis for phosphorylated ATM (pATM), ATM, and MGMT, in BT046 cells treated with temozolomide and radiation, with BMP4 and LY364947 or TGF-β1 and noggin, compared to control. (E) Western blot analysis for phosphorylated H2αX in BT046 cells treated with temozolomide and radiation, with BMP4 and LY364947 or TGF-β1 and noggin, compared to control. (F) Kaplan-Meier curve for survival in NSG mice following intracranial transplantation with U251 or U251-TR cells (*p < 0.01). (G) Circos plot of expression data generated by microarray analysis of U251 cells. (H) Circos plot of expression data generated by microarray analysis of U251-TR cells.